Knee osteoarthritis (OA) is a prevalent chronic, progressive, degenerative condition in older individuals, characterized by ...

Tirzepatide offers more favorable return on investment, but greater benefits seen at lower costs for Roux-en-Y gastric bypass ...

Compared with usual care, GLP-1 receptor agonists tirzepatide and semaglutide may be cost-effective options for patients with ...

Elena Losina, PhD, codirector of the Orthopedics and Arthritis Center for Outcomes Research at Brigham and Women’s Hospital, discusses the cost-effectiveness of varying weight loss interventions.

The global high tibial osteotomy plates market size was US$ 311.06 million in 2021. The global high tibial osteotomy plates market size is forecast to reach US$ 400.3 million by 2030, growing at a ...

Compared with usual care, the glucagon-like peptide 1 receptor agonists (GLP-1 RAs) tirzepatide and semaglutide are cost-effective for people with knee osteoarthritis (OA) and obesity, according to a ...

A man who has suffered two strokes and has a pacemaker, osteoarthritis and one kidney, cycled from London to his home in ...

After a strategy revamp Noxopharm is pursuing a clinical program targeting inflammation, notably the painful condition skin ...

Novo Nordisk , looking to turn around slowing growth of its blockbuster weight-loss drug Wegovy, plans to test whether its ...

Novo Nordisk is planning clinical trials to explore the potential of its weight-loss drugs in treating obesity-related conditions.

Novo Nordisk is broadening its focus beyond obesity and diabetes by exploring the potential of its weight-loss drugs, ...

Now, a team of researchers from the University of Utah, NYU, and Stanford University has discovered a new option: gait ...